South Korea
· Delayed Price · Currency is KRW Aligned Genetics Statistics
Total Valuation
Aligned Genetics has a market cap or net worth of KRW 43.14 billion. The enterprise value is 31.59 billion.
| Market Cap | 43.14B |
| Enterprise Value | 31.59B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aligned Genetics has 14.38 million shares outstanding.
| Shares Outstanding | 14.38M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.84% |
| Owned by Institutions (%) | n/a |
| Float | 6.75M |
Valuation Ratios
The trailing PE ratio is 13.02.
| PE Ratio | 13.02 |
| Forward PE | n/a |
| PS Ratio | 2.89 |
| PB Ratio | 1.32 |
| P/FCF Ratio | 20.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.87, with an EV/FCF ratio of 15.37.
| EV / Earnings | 9.53 |
| EV / Sales | 2.12 |
| EV / EBITDA | 8.87 |
| EV / EBIT | 10.71 |
| EV / FCF | 15.37 |
Financial Position
The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.48 |
| Quick Ratio | 3.53 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 1.32 |
| Debt / FCF | 2.22 |
| Interest Coverage | 13.19 |
Financial Efficiency
Return on equity (ROE) is 10.58% and return on invested capital (ROIC) is 5.00%.
| Return on Equity (ROE) | 10.58% |
| Return on Assets (ROA) | 4.41% |
| Return on Capital (ROIC) | 5.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.37 |
| Inventory Turnover | 0.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.77% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.77% |
| 50-Day Moving Average | 3,242.80 |
| 200-Day Moving Average | 3,912.83 |
| Relative Strength Index (RSI) | 39.22 |
| Average Volume (20 Days) | 28,491 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aligned Genetics had revenue of KRW 14.93 billion and earned 3.31 billion in profits. Earnings per share was 230.50.
| Revenue | 14.93B |
| Gross Profit | 10.61B |
| Operating Income | 2.86B |
| Pretax Income | 3.81B |
| Net Income | 3.31B |
| EBITDA | 3.47B |
| EBIT | 2.86B |
| Earnings Per Share (EPS) | 230.50 |
Balance Sheet
The company has 16.11 billion in cash and 4.56 billion in debt, giving a net cash position of 11.55 billion or 803.12 per share.
| Cash & Cash Equivalents | 16.11B |
| Total Debt | 4.56B |
| Net Cash | 11.55B |
| Net Cash Per Share | 803.12 |
| Equity (Book Value) | 32.74B |
| Book Value Per Share | 2,277.20 |
| Working Capital | 18.22B |
Cash Flow
In the last 12 months, operating cash flow was 2.46 billion and capital expenditures -409.30 million, giving a free cash flow of 2.05 billion.
| Operating Cash Flow | 2.46B |
| Capital Expenditures | -409.30M |
| Free Cash Flow | 2.05B |
| FCF Per Share | 142.91 |
Margins
Gross margin is 71.05%, with operating and profit margins of 19.15% and 22.20%.
| Gross Margin | 71.05% |
| Operating Margin | 19.15% |
| Pretax Margin | 25.52% |
| Profit Margin | 22.20% |
| EBITDA Margin | 23.24% |
| EBIT Margin | 19.15% |
| FCF Margin | 13.76% |
Dividends & Yields
Aligned Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 7.68% |
| FCF Yield | 4.76% |
Stock Splits
The last stock split was on November 7, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Nov 7, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Aligned Genetics has an Altman Z-Score of 4.84.
| Altman Z-Score | 4.84 |
| Piotroski F-Score | n/a |